期刊文献+

2型糖尿病患者初始胰岛素剂量与代谢参数的关系 被引量:3

Relationship between Initial Insulin Dosage and the Metabolic Parameters in Patients with Type 2 Diabetes
下载PDF
导出
摘要 目的:分析2型糖尿病患者初始胰岛素剂量与代谢参数之间的关系,探索更合理估计初始胰岛素剂量的方法。方法:收集初次应用胰岛素治疗的2型糖尿病住院患者164例,询问病史,测量身高、体质量、腰围、臀围、血压,检测空腹血糖、胰岛素、C肽、糖化血红蛋白(HbA1c)、血脂,进行精氨酸试验。结果:2型糖尿病患者的初始胰岛素剂量与胰岛素抵抗指数(HOMA-IR)(r=0.416,P<0.001)、空腹胰岛素(r=0.372,P<0.001)、三酰甘油(TG)(r=0.212,P=0.007)、空腹血糖(r=0.180,P=0.021)、腰围(r=0.170,P=0.029)、精氨酸试验的血糖曲线下面积(r=0.167,P=0.032)呈正相关。在糖尿病病程≤1年的患者中,空腹胰岛素和C肽水平、HOMA-IR是影响初始胰岛素剂量的主要因素,回归方程分别为:初始胰岛素剂量=1.031×空腹胰岛素-2.975×空腹C肽+24.56,或初始胰岛素剂量=1.256×HOMA-IR+22.489。在糖尿病病程>1年的患者中,腰围、TG和空腹血糖水平是影响患者初始胰岛素剂量的主要因素,回归方程分别为:初始胰岛素剂量=0.381×空腹胰岛素-4.506×高密度脂蛋白胆固醇HDL-c+31.83,或初始胰岛素剂量=0.206×腰围+0.585×TG+0.668×空腹血糖+3.709。结论:空腹胰岛素、空腹C肽、HOMA-IR是新诊断2型糖尿病患者的初始胰岛素剂量的主要影响因素。空腹胰岛素、HDL-c、腰围、TG和空腹血糖是病程超过1年的2型糖尿病患者初始胰岛素剂量的影响因素。 Objective:To analyze the relationship between initial insulin dosage for type 2 diabetes(T2D) and the metabolic parameters and to explore a more reasonable method for evaluating the initial insulin dosage.Methods: We enrolled 164 inpatients with T2D who initially treated with insulin and collected their data including personal history,height,weight,waist and hip circumferences,blood pressure and the laboratory examinations including fasting blood glucose,insulin and C peptide,HbAlC,lipid profile.All the patients performed the arginine stimulating test to observe the acute phase secreting function of β cells.Results: The initial insulin dosage for patients with T2D was positively related to HOMA-IR(r=0.416,P0.001),fasting blood insulin(r=0.372,P0.001),triglyceride TG(r=0.212,P=0.007),fasting blood glucose(r=0.180,P=0.021),waist circumference(r=0.170,P=0.029),area under the blood glucose curve in arginine stimulating test(r=0.167,P=0.032).In the patients with a diabetes history no more than 1 year,fasting blood insulin and C peptide,HOMA-IR were the main impact factors and the regression equations were respectively as follows,initial insulin dosage=1.031×fasting blood insulin-2.975×fasting C peptide+24.56,and initial insulin dosage=1.256×HOMA-IR+22.489;on the other hand,among patients with a diabetes history more than 1 year,waist circumference,TG and fasting blood glucose were the main impact factors,the regression equations were respectively as follows,initial insulin dosage = 0.381×fasting blood insulin-4.506×HDL-c+31.83,and initial insulin dosage=0.206×waist circumference+0.585×TG+ 0.668×fasting blood glucose+3.709.Conclusions: Fasting blood insulin,fasting C peptide,HOMA-IR were the main impact factors of the initial insulin dosage for newly diagnosed type 2 diabetic patients.Fasting blood insulin,HDL-c,waist circumference,TG and fasting blood glucose are the impact factors of the initial insulin dosage for type 2 diabetic patients with a history more than 1 year.
出处 《中国临床医学》 2010年第4期530-532,共3页 Chinese Journal of Clinical Medicine
关键词 糖尿病 胰岛素剂量 代谢参数 Diabetes Insulin dosage Metabolic parameter
  • 相关文献

参考文献4

  • 1Campbell IW.Need for intensive,early glycaemic control in patients with type 2 diabetes[J].Br J Cardiol,2000,7:625-31.
  • 2Weng JP,Li YB,Yanbing Li,et al.Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes:a multicentre randomised parallel-group trial[J].The Lancet,2008,371:1753-1760.
  • 3Defronzo RA.Pathogenesis of type 2 diabetes mellitus[J].Med Clin N Am 2004,88:787-835.
  • 4王芳,刘军,陈灶萍,查兵兵,查英,丁和远,盛励,廖晓寰.2型糖尿病家系非糖尿病一级亲属胰岛素抵抗与胰岛β细胞功能变化5年随访研究[J].中国临床医学,2009,16(2):232-234. 被引量:7

二级参考文献8

  • 1刘军,陈影,刘芳,姚庆姑,许火根,澎名淑,郭瑜琳,陈钦达.2型糖尿病家系非糖尿病一级亲属脂联素水平与胰岛素抵抗和动脉粥样硬化相关性研究[J].中华内分泌代谢杂志,2004,20(3):215-216. 被引量:30
  • 2薛云,成金罗,胡继红,沈默宇,张允平.2型糖尿病家系非糖尿病一级亲属第一时相胰岛素的变化[J].中国临床医学,2006,13(6):968-969. 被引量:2
  • 3Tura A, Mari A, Winzer C, et al. Impaired beta-cell function in lean normotolerant former gestational diabetic women[J]. Eur J Clin Invest,2006,36 : 22-28.
  • 4Mari A, Gastaldelli A, Natali A,et al. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects:modeling analysis of 24h trip le-meal tests[J].Am J Physiol Endocrinol Metab, 2005,288:541-546.
  • 5Amer P, Pollare T, Lithell H. Different etiologies of type 2 (noninsulin-dependent) diabetes mellitus in obese and nonobese subjects[J].Diabetologia, 1991,34:483-487.
  • 6Haeften van TW, Pimenta A, Mitrakou A, et al. Relatively contribution of β-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia[J]. Metabolism, 2000,49:1318- 1325.
  • 7Amoah AG, Owusu SK, Schuster DP, et al. Pathogenic mechanism of type 2 diabetes in Ghanaians the importanee of beta cell secretion, insulin sensitivity and glucose effectiveness[J]. S Aft Med, 2002,92 : 377-384.
  • 8Pimenta W, Korytkowski M, Mitrakon A, et al. Pancreatic bete-cell dysfunction as the primary genetic lesion in NIDDM[JJ. JAMA, 1995. 273 : 1855-1861.

共引文献6

同被引文献31

  • 1卜石,邢小燕,王娜,赵文惠,杨文英.长效胰岛素联合口服降糖药治疗2型糖尿病的疗效与安全性[J].中国循证医学杂志,2004,4(7):464-467. 被引量:157
  • 2潘长玉,田慧,刘国良,李秀钧,傅祖植,陈家伟,暨亚洲糖尿病管理中国协作组.中国城市中心医院糖尿病健康管理调查[J].中华内分泌代谢杂志,2004,20(5):420-424. 被引量:193
  • 3李东锋,杨波,杨汉东,汤天军,闵新文,李毅,张宾.代谢综合征患者血清抵抗素与血脂、肥胖和胰岛素抵抗关系的研究[J].中国临床医学,2005,12(2):206-208. 被引量:12
  • 4张良岩,李翠华,伊婕,杨乃龙.亚莫利分别与来得时、NPH联合治疗比较[J].实用糖尿病杂志,2006,2(6):16-17. 被引量:16
  • 5Wright A,Burden AC,Paisey RB.Sulfonylurea Inadequacy:Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK prospective diabetes study(UKPDS 57)[J].Diabetes Care,2002,25(2):330-336.
  • 6Nathan DM,Buse JB,Davidson MB,et al.Medical management of hyperglycemia in type 2 diabetes:A consensus algorithm for the initiation and adjustment of therapy[J].Diabetes Care,2008,31(1):173-175.
  • 7Forst T,Larbig M,Hobberg C,et al.Adding insulin glargine vs.NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes[J].Diabetes Obes Metab,2010,12(5):437-441.
  • 8Gordon J,Pockett RD,Tetluw AP,et al.A comparison of intermediate and long-acting insulins in people with type 2 diabetes startinginsulin:an observational database study[J].Int J Clin Pract,2010,64(12):1609-1618.
  • 9Gillies PS,Figgitt DP,Lamb HM.Insulin glargine[J].Drugs,2000,59(2):253-262.
  • 10Davies M,Storms F,Shutler S,et al.Improvement of glycemic control in subjects with poorly controlled type 2 diabetes:comparison of two treatment algorithms using insulin glargine[J].Diabetes Care,2005,28(6):1282-1288.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部